TWiV explains that a recent report suggesting that the SARS-CoV-2 spike protein inhibits V(D)J recombination in vitro would not impact immunity after infection or vaccination, and describes the isolation of remdesivir resistant mutants in cells in culture, and the emergence of amino acid changes in the spike protein identical to those in variants of concern, in the absence of immune selection.
The complete TWiV team reviews identification of the cell receptor for hepatitis B and D viruses, and the cell enzyme that cleaves the genome-linked protein from picornaviral RNA.
The Hosts of TWiV
Vincent Racaniello, Ph.D.
Dickson D.
Despommier, Ph.D.
Alan Dove, Ph.D.
Daniel Griffin, M.D.,
Ph.D., CTropMed CTH
Jolene Ramsey, Ph.D.